El interés en corto de Xilio Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Xilio Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Xilio Therapeutics (NASDAQ:XLO) Bolsa, Informe de interés en corto

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Xilio Therapeutics Inc

On Thursday, Cathie Wood-led Ark Invest made notable trades, prominently featuring Tempus AI Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) and Coinbase Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>). The trades came as Wall Street <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44744139/wall-street-tumbles-dollar-crashes-gold-hits-record-highs-as-inflation-cools-more-than-predicted-whats-driving-markets-thursday">reversed Wednesday's rally</a> with a sharp selloff, as cooling inflation and hopes for Fed cuts were overshadowed by economic uncertainty and a 145% China tariff announcement by the Trump administration.
The Tempus AI Trade
Ark Invest&#8217;s flagship fund, the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), acquired 48,909 shares of Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), valued at approximately $1.97 million based on the closing price of $40.29.
Tempus AI has been gaining attention for its advancements in AI-driven healthcare solutions. Ark has been trading shares of the company actively. Last week, it <a href="https://www.benzinga.com/25/04/44704064/cathie-wood-loads-up-on-18-2-million-worth-of-nvidia-stock-adds-5-8-million-worth-of-amazon-shares-to-her-shopping-cart-amid-trump-tariff-upheaval">scooped up</a> stock worth $1.74 million.
The Coinbase Trade
In another significant move, ARKK purchased 11,849 shares of Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), amounting to approximately $2.01 million based on the closing price of $169.62. This acquisition comes at a time when the regulatory landscape for cryptocurrency trading in the U.S. is evolving, potentially making crypto leverage trading <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44739006/crypto-leverage-trading-in-the-us-may-become-more-accessible-heres-why">more accessible</a> to retail investors.
Coinbase, a leading cryptocurrency exchange, has announced plans to introduce a first-of-its-kind perpetual-style product in the U.S. and is also reportedly in talks to acquire crypto derivatives exchange Deribit
Other Key Trades:
<ul>
<li>ARKK bought 135,247 shares of Beam Therapeutics Inc. (BEAM).</li>
<li>ARKG sold 33,500 shares of Repare Therapeutics Inc. (RPTX).</li>
<li>ARKK acquired 191,500 shares of 10X Genomics Inc. (TXG).</li>
</ul>
How does Coinbase rank against other crypto picks? <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Find out</a> with Benzinga Edge Stock Rankings.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="794" height="109" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10215544/Screenshot-2025-04-11-at-10.55.27.png" alt="" class="wp-image-867031" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10215544/Screenshot-2025-04-11-at-10.55.27.png 794w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10215544/Screenshot-2025-04-11-at-10.55.27-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10215544/Screenshot-2025-04-11-at-10.55.27-768x105.png 768w" sizes="(max-width: 794px) 100vw, 794px" /></a></figure>
Image via Shutterstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44753854/alibaba-jpmorgan-carmax-janover-tesla-why-these-5-stocks-are-on-investors-radars-today">Alibaba, JPMorgan, Carmax, Janover, Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

News

Markets

ETFs

ARKK

COIN

Cathie Wood's Thursday Plays: Healthcare AI And Crypto — Ark Scoops Up Tempus AI and Coinbase Stock Amid Trump Tariff Crash

National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
National Health Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NHI#NYSE">NHI</a>) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.
It is set to report its Q1 2025 earnings on May 5. Wall Street analysts expect the company to post EPS of $1.13, up from $1.12 in the prior-year period. According to Benzinga Pro, quarterly revenue is expected to reach $85.13 million, up from $81.51 million a year earlier.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">If You Bought National Health Investors Stock 10 Years Ago</h2>
The company's stock traded at approximately $70.66 per share 10 years ago. If you had invested $10,000, you could have bought roughly 142 shares. Currently, shares trade at $70.20, meaning your investment's value could have declined to $9,935 from stock price depreciation. However, National Health Investors also paid dividends during these 10 years.&nbsp;
National Health Investors' dividend yield is currently 5.04%. Over the last 10 years, it has paid about $38.91 in dividends per share, which means you could have made $5,507 from dividends alone.&nbsp;
Summing up $9,935 and $5,507, we end up with the final value of your investment, which is $15,442. This is how much you could have made if you had invested $10,000 in National Health Investors stock 10 years ago. This means a total return of 54.42%. However, this figure is significantly less than the S&amp;P 500 total return for the same period, which was 193.10%.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">What Could The Next 10 Years Bring?&nbsp;</h2>
National Health Investors has a consensus rating of "Hold" and a price target of $68 based on the ratings of 14 analysts. The price target implies a more than 3% potential downside from the current stock price.
On Feb. 25, the company announced its Q4 2024 earnings, posting FFO of $1.12, compared to the consensus of $1.11, and revenues of $85.75 million, compared to the consensus of $82.67 million, as reported by <a href="https://www.benzinga.com/news/earnings/25/02/43957300/national-health-investors-q4-2024-ffo-1-12-beats-1-11-estimate-sales-85-75m-beat-82-67m-estimate">Benzinga.</a>
&#8220;The fourth quarter results exceeded our internal expectations as fundamentals remain strong throughout the portfolio with continued improvement in EBITDARM coverage trends, year-over-year cash rental income growth of 8.6%, SHOP NOI growth of 12.5%, and positive contributions from acquisitions completed during the year,&#8221; said CEO Eric Mendelsohn.
See Also: If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?
The company provided its full-year 2025 guidance, expecting normalized FFO attributable to common stockholders in the range of $214.7 million to $218.1 million.
Given the expected downside potential, growth-focused investors may not find National Health Investors stock attractive. Conversely, the stock can be a good option for income-focused investors, who can benefit from the company's solid dividend yield of 5.04%.
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44659667/why-manpowergroup-regions-financial-and-nexstar-mediaare-winners-for-passive-income">article by Benzinga</a> for three more stocks offering high dividend yields.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

If You Invested $10K In National Health Investors Stock 10 Years Ago, How Much Would You Have Now?

After a remarkable rally on Wednesday, Wall Street <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44744139/wall-street-tumbles-dollar-crashes-gold-hits-record-highs-as-inflation-cools-more-than-predicted-whats-driving-markets-thursday">experienced a sharp decline</a> on Thursday. Investors were cautious as they assessed the implications of President Donald Trump&#8217;s 90-day tariff pause amidst ongoing economic uncertainties. The S&amp;P 500 fell by 3.5% to 5,268.05, while the Nasdaq 100 dropped by over 4.3% to 16,387.31. The Dow Jones Industrial Average declined 2.5% to 39,593.66. Despite a lower-than-expected inflation report, the market&#8217;s risk sentiment remained fragile.
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)
Alibaba&#8217;s stock dipped 0.57% to close at $104.18, with an intraday high of $108.45 and a low of $101.37. The stock&#8217;s 52-week range is $148.43 to $68.36. Alibaba co-founder Jack Ma made a <a href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback">public appearance</a> at the company&#8217;s cloud campus, marking its 15th anniversary. The cloud unit introduced the Blossom project, aimed at accelerating AI adoption.
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)
JPMorgan&#8217;s shares fell 3.09% to $227.11, with a high of $230.35 and a low of $220.10. The 52-week range is $280.25 to $179.20. Bank stocks including JPMorgan <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44750118/bank-stocks-drop-as-market-pulls-back-following-historic-rally-whats-going-on">reversed gains</a> from the previous session, as the market pulled back following a historic rally driven by a temporary tariff pause. JPMorgan will release its <a href="https://www.benzinga.com/insights/earnings/25/04/44736126/a-preview-of-jpmorgan-chases-earnings">latest quarterly numbers</a> on Friday. Analysts estimate that the banking giant will report an earnings per share of $4.64.
CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>)
CarMax&#8217;s stock plummeted 17.00% to $66.45, with a high of $71.55 and a low of $63.23, which is also its 52-week low. The 52-week high is $91.25. CarMax reported <a href="https://www.benzinga.com/25/04/44733776/carmax-accelerates-with-6-growth-in-used-car-sales-despite-earnings-miss">fourth-quarter sales</a> of $6 billion, beating estimates, with retail used unit sales up 6.2% year-over-year and EPS at 58 cents, missing expectations. Gross profit per retail unit rose to $2,322, and the company repurchased 1.2 million shares for $98.5 million. For FY26, it plans to open six new stores and spend around $575 million in capital expenditures.
Janover Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>)
Janover&#8217;s stock surged 64.24% to $44.97, reaching a high of $61.36 and a low of $27.20. The 52-week range is $61.36 to $3.37. Janover <a href="https://www.benzinga.com/trading-ideas/previews/25/04/44749409/janover-stock-soars-after-company-acquires-solana-under-new-treasury-strategy-whats-going-on">announced the acquisition</a> of $4.6 million worth of Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) as part of its new digital asset treasury strategy.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla&#8217;s stock dropped 7.27% to $252.40, with an intraday high of $262.49 and a low of $239.33. The 52-week range is $488.54 to $138.80. Tesla began selling its vehicles in Saudi Arabia, <a href="https://www.benzinga.com/25/04/44728787/tesla-to-make-saudi-arabia-debut-amid-infrastructure-challenges">expanding its global footprint</a> despite declining sales in Europe.
Benzinga Edge Stock Rankings indicate JPMorgan has a Momentum in the 87th percentile but Growth in only 60th Percentile. How does it compare with other potent banking rivals? Find out by <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">clicking here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="796" height="107" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10211544/Screenshot-2025-04-11-at-10.15.09.png" alt="" class="wp-image-866996" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10211544/Screenshot-2025-04-11-at-10.15.09.png 796w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10211544/Screenshot-2025-04-11-at-10.15.09-300x40.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10211544/Screenshot-2025-04-11-at-10.15.09-768x103.png 768w" sizes="(max-width: 796px) 100vw, 796px" /></a></figure>
Prepare for the day&#8217;s trading <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a> by Benzinga.
Photo Courtesy: Shutterstock.com
Read Next: 
<ul>
<li><a href="https://benzinga.com/markets/cryptocurrency/25/04/44726952/trump-media-surges-after-hours-following-a-21-rally-makes-potus-richer-by-410-millionoffic" target="_blank" rel="noreferrer noopener">Trump Media Surges After Hours Following A 21% Rally, Makes POTUS Richer By $410 Million—Official Trump Memecoin Also Gains</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

$SOL

BABA

JNVR

TSLA

Alibaba, Jpmorgan, Carmax, Janover, Tesla: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock futures fell on Thursday night as investors prepared to close a volatile trading week marked by dramatic market swings. 
Nasdaq-100 futures led declines, dropping 1.26% to 18,251.75, while S&amp;P 500 futures fell 1.04% to 5,247.00 and Dow futures slipped 0.88% to 39,448.00.
Japan's Nikkei 225 tumbled 5.39% to 32,744.89 in early Friday trading, shedding 1,864 points amid global market volatility. U.S. Treasury yields rose, with the 10-year up 8.4 basis points to 4.47% and the 30-year up 9.6 basis points to 4.94%.
Gold prices surged, with June COMEX contracts rising 1.61% to $3,228.60 as demand for safe-haven assets increased.
Markets remain on edge after President Donald Trump rolled out a temporary 10% universal tariff on most imports, while slapping China with a steep 145% duty, the White House <a href="https://www.cnbc.com/2025/04/10/trumps-triple-digit-tariff-essentially-cuts-off-most-trade-with-china-says-economist.html">told</a> CNBC. Still, Trump struck a hopeful tone, expressing confidence in eventually <a href="https://in.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns">reaching a deal with Beijing</a>.
&#8220;Would love to be able to work a deal with China,&#8221; Trump <a href="https://www.benzinga.com/government/regulations/25/04/44748635/stocks-bounce-off-session-lows-after-trump-says-china-deal-is-going-to-work-out">told reporters at the White House</a>. &#8220;I think we will end up working out something good for both nations.&#8221;
The comments helped major indexes trim earlier losses, with the S&amp;P 500 tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed at 5,268, down 3.46% after falling more than 4% midday. The Nasdaq-100, tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), lost 4.19%, dropping to the 18,343 level.
Traders will face additional catalysts on Friday, including major bank earnings from JPMorgan Chase &amp; Co. and Wells Fargo &amp; Co., along with crucial March <a href="https://www.benzinga.com/25/04/44751312/wall-street-on-edge-bank-earnings-inflation-data-consumer-sentiment-set-stage-for-friday-fireworks">producer price inflation data</a> that could influence Federal Reserve policy decisions.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44752456/obama-era-economist-jason-furman-says-trump-tariffs-now-higher-more-inflationary-than-announced-rais">Obama-Era Economist Jason Furman Says Trump Tariffs &#8216;Now Higher &amp; More Inflationary&#8217; Than Announced: Raising China Levies Outweighs 90-Day Delay On Others</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

US Stock Futures Fall, Nikkei Crashes Over 5% As Markets Reel From Trump's Tariff Shock

The U.S. government has spent roughly $40 million in just six weeks to detain fewer than 400 migrants at the <a href="https://www.benzinga.com/news/global/25/01/43350606/trump-pledges-to-send-up-to-30000-migrants-to-guantanamo-bay-detention-facility">Guantánamo Bay</a> Naval Base in Cuba, according to estimates shared by anonymous congressional aides with <a href="https://www.nytimes.com/2025/03/31/us/politics/migrants-guantanamo-costs.html#">The New York Times</a>. This operation, part of President Donald Trump's broader immigration enforcement efforts, has raised serious concerns among lawmakers, particularly regarding its high cost and military impact.
A Senate delegation visited Guantánamo in late March to assess the mission. The lawmakers toured the facilities, met with service members and officials, and came away highly critical of the effort. Sen. Jack Reed of Rhode Island, the ranking Democrat on the Senate Armed Services Committee, told The Times that the operation is "extraordinarily expensive and unnecessary," saying those resources could be better used to strengthen existing immigration facilities in the US.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-private-credit-fund">Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom</a></li>
</ul>
<h2 class="wp-block-heading">Why Guantánamo?</h2>
The decision to use Guantánamo Bay, known for housing terrorism suspects, for immigration detention is both logistically complex and financially burdensome. The base is isolated from the rest of Cuba by a minefield and must generate its own electricity and water supply. Supplies are flown or shipped in from Florida. As a result, housing even a small number of people there comes at a steep cost.
Since February, the <a href="https://www.benzinga.com/news/25/02/43882547/dhs-fires-fema-officials-after-deep-state-activists-sent-59m-to-nyc-migrant-hotels-trump-admin-claws-it-back">Department of Homeland Security</a> has transferred about 400 migrants to the base, many of them Venezuelan. Roughly half have since been moved back to the US or deported. At one point, as few as 85 people were being held, even as nearly 1,000 U.S. government employees, mostly military personnel, were assigned to the mission.
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
<h2 class="wp-block-heading">Military Involvement Raises Concerns</h2>
Lawmakers are also questioning the use of military resources for a task traditionally handled by civilian immigration authorities. In a joint <a href="https://www.reed.senate.gov/news/releases/after-visiting-guantanamo-bay-senators-blast-trump-admin-for-wasting-taxpayer-dollars-and-misusing-military-resources">statement</a>, Sens. Reed, Jeanne Shaheen, Gary Peters, Alex Padilla, and Angus King said that troops were "rushed to Guantánamo Bay without notice, leaving their critical day-to-day military missions behind in order to build tents that should never be filled and guard immigrants who should never be held there."
The senators emphasized that their concern lies with the mission — not the service members. "Our troops in Guantánamo have a uniquely difficult, demanding job," the statement read, praising their professionalism. Still, the lawmakers argued that using Guantánamo for migrant detention diverts military focus and may even be legally questionable.
<h2 class="wp-block-heading">Legal and Transparency Questions Remain</h2>
So far, the administration has offered little public explanation about who is being sent to Guantánamo and why. A secret agreement between the Department of Defense and Homeland Security reportedly allows for the transfer of migrants with ties to transnational criminal organizations. However, some individuals sent to the base were only found to have crossed the border illegally — some more than once — but without any known violent criminal history.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
According to The Times, the most recent detainees included Nicaraguans described by DHS as "gang members," though the government has not provided supporting details. Questions about the operation's legality and oversight continue to draw scrutiny, particularly from members of Congress who say they've been kept in the dark.
<h2 class="wp-block-heading">Calls for an End to the Program</h2>
Following their visit, the senators urged the Trump administration to "immediately cease this misguided mission," calling it "unsustainably expensive" and "harmful to our military readiness." Despite their statement, U.S. Immigration and Customs Enforcement transported more migrants to the base just hours after their visit ended.
While <a href="https://www.benzinga.com/25/03/44447338/donald-trump-administration-to-strip-legal-protections-from-over-half-a-million-migrants-as-he-argues-joe-bidens-parole-programs-overstepped-federal-law">immigration enforcement</a> remains a central political issue, the Guantánamo operation raises new questions about cost, efficiency, and the role of the military in civilian matters. For now, one thing is clear: the use of this high-security base for a small group of migrants has sparked a heated debate—one likely to continue in the months ahead.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

A 'Waste of Resources'? U.S. Spent $40 Million To Hold 400 Migrants At Guantánamo In Just 6 Weeks

<ul>
<li>Federal Reserve Governor Christopher Waller says he's "a big advocate of stablecoins"</li>
<li>Voicing his support for stablecoin acts like the GENIUS act and the STABLE act, he says he sees no need for the government to develop a coin of its own</li>
<li>"I prefer to let the private sector handle these problems," he told audiences at a NY Fed event</li>
</ul>
Federal Reserve Governor Christopher Waller said that he's a fan of stablecoins and believes they have a place in the payment system, but does not see the need for the government to adopt one of their own.&nbsp;
"I&#8217;ll say I&#8217;m a personal, big advocate of stablecoins. I have been saying this for over three-plus years now, about how this could bring competition, efficiency and speed into the payments system,&#8221; he told audience members at a conference held by the Federal Reserve Bank of New York on Friday, according to <a href="https://www.reuters.com/technology/feds-waller-stablecoins-bring-benefits-payment-system-2025-04-04/">Reuters</a>.&nbsp;
Don't Miss:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
A stablecoin is a type of cryptocurrency that is designed to have a stable price. Their value is attached to that of another asset, like gold or a government-issued currency, in order to maintain a more consistent value. Originally designed to help bridge the gap between traditional finance and cryptocurrencies, there are currently around 200 globally distributed stablecoins on the market.&nbsp;&nbsp;
Recently, two stablecoin-oriented bills have been working their way through Congress. The Guiding and Establishing National Innovation for U.S. Stablecoins of 2025, or the <a href="https://www.congress.gov/bill/119th-congress/senate-bill/394/text/is">GENIUS Act of 2025</a>, and the Stablecoin Transparency and Accountability for a Better Ledger Economy Act of 2025, or the <a href="https://www.congress.gov/bill/119th-congress/house-bill/2392/text/ih?overview=closed&amp;format=xml">STABLE Act of 2025</a>, both seek to provide a comprehensive regulatory framework for stablecoins. The difference between the bills lies in their scope and approach, but the passing of either one would increase the chances of Congress passing a law certifying stablecoins as a global financial tool.&nbsp;
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
Thus far, stablecoin legislation has received bipartisan support. But Waller said Friday that he saw no need for the government to create its own stablecoin should either of the bills pass. "I prefer to let the private sector solve these problems,&#8221; Reuters quoted him as saying. &#8220;It&#8217;s not my job as an unelected bureaucrat to tell everybody how they should do things."
As for the concerns that tons of new stablecoins will flood the market should the legislation pass, Waller said watchers shouldn't worry. "I don't think… there's going to be 100 stablecoins circulating after the legislation happens." Though two companies, Tether and Codex, have already indicated that they will make moves to establish their own stablecoins in the US as soon as there are regulations firmly in place, according to the <a href="https://www.ft.com/content/1b3cccad-ad33-4dd9-b2b6-1514f80e39ad">Financial Times</a> and <a href="https://fortune.com/crypto/2025/04/04/codex-seed-round-dragonfly-coinbase-circle-15-8-million/">Fortune</a>.&nbsp;
Waller's stance on crypto aligns with President Donald Trump's, who promised last month to make the US "the crypto capital of the world."&nbsp;
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>

Federal Reserve Governor Says He's A 'Big Advocate Of Stablecoins,' But Wants The Government To Steer Clear Of Own Crypto

MULN

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

HCWB

AMRN

Former House Speaker Nancy Pelosi (D-CA) blasted President Donald Trump over his tariff policy last week, warning that it could result in serious economic damage for American families. She also invoked Republican icon Ronald Reagan to drive home her point.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Trump Administration&#39;s flagrant ineptitude is tanking our economy in a self-inflicted disaster that leaves hardworking American families bearing the brunt of the pain. Make no mistake: President Trump&#39;s senseless tariffs will drive prices higher, drain retirement savings and…
&mdash; Nancy Pelosi (@SpeakerPelosi) <a href="https://twitter.com/SpeakerPelosi/status/1908238636346466795?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
&#8220;President Trump&#8217;s senseless tariffs will drive prices higher, drain retirement savings and push us to the brink of recession,&#8221; Pelosi <a href="https://x.com/SpeakerPelosi/status/1908238636346466795">posted</a> on X just days after Trump&#8217;s so-called &#8220;Liberation Day.&#8221; She described the situation as a &#8220;self-inflicted disaster&#8221; and accused the Trump administration of <a href="https://www.benzinga.com/25/04/44661965/trumps-reciprocal-tariff-threat-wipes-out-nearly-18-trillion-from-magnificent-7-dan-ives-warns-it-could-set-us-tech-back-a-decade-investors-know-math-and-the-sad-reality">tanking the economy</a> through what she called &#8220;flagrant ineptitude.&#8221;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
<h2 class="wp-block-heading">Referencing Reagan</h2>
To reinforce her message, Pelosi <a href="https://www.benzinga.com/markets/25/03/44269552/ronald-reagan-warned-that-tariffs-destroy-prosperity-trump-is-doubling-them-anyway-and-now-us-tech-giants-like-apple-and-nvidia-are-bracing-for-impact">quoted Reagan</a>: &#8220;We should beware of the demagogues who are ready to declare a trade war against our friends – weakening our economy, our national security, and the entire free world – all while cynically waving the American flag.&#8221; She added, &#8220;President Reagan's words were true then and they're true today.&#8221;
She also urged Republicans in Congress to reconsider their support for Trump's trade agenda.
<h2 class="wp-block-heading">Medicaid Cuts and Tax Breaks for Billionaires</h2>
Just weeks earlier, <a href="https://www.benzinga.com/25/02/43612979/nancy-pelosi-says-extreme-maga-republicans-have-revealed-their-tax-scam-to-plunder-medicaid-for-giving-tax-cuts-to-billionaires">Pelosi took aim</a> at what she called a &#8220;tax scam&#8221; by &#8220;extreme MAGA Republicans&#8221; that she claims is designed to slash Medicaid in order to fund tax breaks for billionaires.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
&#8220;Extreme MAGA Republicans revealed their tax scam to raid Medicaid to give more tax cuts to billionaires,&#8221; she <a href="https://x.com/TeamPelosi/status/1889100925673054462">shared</a> on X. &#8220;But we can stop them! We&#8217;ve done it before — we saved Social Security in 2006, the Affordable Care Act in 2018 and we&#8217;ll stop them now to save the ACA, Medicare and Medicaid.&#8221;
Pelosi described Republican efforts in Congress as &#8220;unbearable for people on Medicare and Medicaid,&#8221; and called for public pressure to stop the cuts, urging &#8220;outside mobilization.&#8221;
The Trump administration&#8217;s agenda has been stalled in Congress because of internal Republican disagreements on how deep the cuts to Medicaid should go.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">Broader Context and Fallout</h2>
The debate over tariffs and spending cuts comes amid other major moves by the Trump administration. A temporary freeze on federal grants and loans has put $3 trillion in funding under review. Around the same time, the <a href="https://www.benzinga.com/25/01/43294006/trump-white-house-blames-outage-for-medicaid-website-lockout-we-have-confirmed-no-payments-have-been-affected">Medicaid website experienced an outage</a>, which the White House blamed on a technical issue.
The Department of Government Efficiency, headed by Elon Musk, has also begun auditing the Centers for Medicare and Medicaid Services, with Musk claiming there is &#8220;big money fraud&#8221; in the system. The agency is under pressure to cut at least $1 trillion in federal spending.
<h2 class="wp-block-heading">Pelosi&#8217;s Market Losses</h2>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wow. Nancy Pelosi has now lost $12M in the stock market in the last two days. Down another $4.5M today. <a href="https://t.co/v4dmOwI8FO">pic.twitter.com/v4dmOwI8FO</a>
&mdash; Quiver Quantitative (@QuiverQuant) <a href="https://twitter.com/QuiverQuant/status/1908210434005504178?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As the policy and tariff debates play out, Pelosi&#8217;s personal finances are also drawing attention. According to <a href="https://x.com/QuiverQuant/status/1908210434005504178">Quiver Quantitative</a>, she has lost $12 million in the stock market over just two days, including a $4.5 million drop on April 4 alone.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

'Trump's Tariffs Will Drain Retirement Savings, Push Us To The Brink Of Recession,' Says Nancy Pelosi While Quoting Ronald Reagan

You may want that new car. The smell, the shine, the 0% financing—what's not to love?
But Dave Ramsey just reminded everyone why that shiny $72,000 BMW might actually be torching your financial future. In a <a href="https://www.facebook.com/share/r/16FzUzF3Aa/?mibextid=wwXIfr">viral Facebook post</a>, he dropped a meme featuring Adam Sandler green-screened into a car dealership, shaking his head, saying "No, no, no, don't say that," before punching a wall in frustration. The caption?
"When you're trading in your $72K BMW and the dealer offers you $17K but you still owe $49K on it."
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
And Ramsey didn't stop there. He followed it up with a caption that hits harder than a monthly payment:
"That $72,000 BMW isn't just costing you a car payment. It's costing you your future."
He's not exaggerating. <a href="https://www.experian.com/blogs/ask-experian/average-car-loan-interest-rates-by-credit-score/">According to Experian</a>, the average new car loan now clocks in at $40,927, with monthly payments pushing $734 for 68.4 months. Meanwhile, car values plummet the second you drive off the lot.&nbsp;
"Let me break it down: Open your car window on the way to work once a week and toss out a $100 bill. That's what driving a new car really costs you."
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
He's not just talking about luxury vehicles, either. Even a "reasonable" $28,000 new car will lose around $17,000 in value over four years. That's about $100 a week in pure depreciation—money that vanishes whether you're financing at 7% or zero.
Ramsey's take on 0% interest? Not impressed."Even 0% interest isn't a deal. It's a distraction from the $17K you just lost in depreciation. You didn't get a car. You got taken."
Here's his rule: "No, you can't afford a new car <a href="https://www.benzinga.com/25/03/44389799/why-dave-ramsey-says-your-typical-millionaire-may-look-just-like-your-next-door-neighbor">unless you are a millionaire</a> and can, therefore, afford to lose thousands of dollars, all in the name of the neat new-car smell."
He's not saying you'll never own a new car. But if dropping tens of thousands without blinking isn't an option, you're not ready for that kind of luxury.&nbsp;
"Until you have <a href="https://www.benzinga.com/24/11/42122576/dave-ramsey-guarantees-if-you-have-a-car-payment-you-will-be-broke-your-whole-life-heres-how-he-says-you-can-become-rich">so much money you can lose big bucks</a> and not notice, you can't afford the luxury."
See Also: <a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a>
Want to know what most millionaires drive? It's not a brand-new German badge with 48 payments attached.
"Most millionaires drive two-year-old used cars with no payments—not because they're too cheap to buy new, but because they know how money works."
And that's the real lesson. You might think you're buying freedom, style, status—but if you're not careful, you're buying debt, depreciation, and regret.
So before you fall for the 0% APR pitch, remember what Ramsey said. You didn't get a deal. You got taken.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>

Dave Ramsey Says If You Want To Know What Driving A New Car Really Costs, 'Open Your Car Window Once A Week And Toss Out A $100 Bill'

BofA Securities analyst Craig Siegenthaler downgraded Cboe Global Markets Inc. (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Buy to Neutral, lowering the price <a href="https://www.benzinga.com/quote/CBOE/analyst-ratings" target="_blank" rel="noreferrer noopener">target to $227 from $260</a>.
The analyst noted that while the broader diversified financials sector has declined 10% year-to-date amid the growing tariff dispute, CBOE Global Markets has stood out by delivering a 5% return —outperforming its peers by about 15%.
This strong performance, according to Siegenthaler, is largely attributed to CBOE&#8217;s defensive business model, which tends to benefit during periods of heightened market volatility and increased trading volumes.
However, despite the solid year-to-date gains, the analyst expressed caution going forward.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44738776/versace-goes-prada-capris-big-exit-sparks-fashion-power-shift" rel="noreferrer noopener">Versace Goes Prada: Capri&#8217;s Big Exit Sparks Fashion Power Shift</a>
The stock's recent outperformance has led to a &#8220;higher relative valuation&#8221; compared to peers.
Siegenthaler pointed out that CBOE&#8217;s next 12 months, or NTM price-to-earnings ratio, has increased by 2% so far this year, while the average PE multiple for the broader diversified financials sector has dropped by 13%. As a result, CBOE now appears about 15% more expensive compared to its peers on a relative valuation basis.
The analyst also pointed to potential deceleration in trading volumes during the second half of 2025, which could weigh on future performance.
Siegenthaler writes that the first half of 2025 will likely mark the cyclical peak for exchange volumes, with a significant decline expected in the second half.
The analyst projects a 6% drop in volumes from the first to the second half of the year, and only a 7% year-over-year increase in total options volume for 2H25.
The analyst is especially concerned about the retail trading segment, where participation may fall due to poor investor performance so far this year.
Siegenthaler lowered earnings estimates for the second half of 2025 and the following years.
The new projections are $4.60 for the second half of 2025, $9.89 for 2026, and $11.37 for 2027 — down from previous estimates of $5.07, $11.16, and $12.99, respectively.
CBOE Price Action: CBOE shares closed Thursday up 2.05% to $210.02.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44731044/jim-cramer-says-pre-market-slide-driven-by-profit-takers-shorts-are-trying-to-figure-whether-to-operate-on-nvidia-avgo-aapl" target="_blank" rel="noreferrer noopener">Jim Cramer Says Pre-Market Slide Driven By Profit-Takers: ‘Shorts Are Trying To Figure Whether To Operate On Nvidia, AVGO, AAPL'</a></li>
</ul>

Options

Analyst Ratings

Movers

Trading Ideas

General

CBOE

CBOE Loses Its Edge? Analyst Downgrades Stock On Valuation Worries, Volume Slowdown

Goldman Sachs analyst Mark Delaney upgraded BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from Neutral to Buy, <a target="_blank" href="https://www.benzinga.com/quote/BWA/analyst-ratings" rel="noreferrer noopener">with a price forecast of $34</a>.
Per Delaney, BorgWarner has a below-average level of U.S. imports, which means it faces relatively limited risk from ongoing or future tariffs.
In contrast to many Western suppliers that have struggled in China due to an unfavorable customer mix, BorgWarner stands out with a stronger positioning in the region.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44746593/goldman-sachs-hits-the-brakes-auto-tariffs-slumping-demand-may-shake-up-ford-tesla-rivian-lear-visteon" rel="noreferrer noopener">Goldman Sachs Hits The Brakes: Auto Tariffs &amp; Slumping Demand May Shake Up Ford, Tesla, Rivian, Lear &amp; Visteon</a>
Around 20% of the company's total revenue comes from China, and approximately 75% is tied to domestic Chinese original equipment manufacturers (OEMs). About 90% of its eProduct business in China is also linked to these domestic OEMs.
Delaney highlighted that BorgWarner's hybrid and internal combustion engine products are expected to have a longer runway, and the company's broad portfolio—which includes products for all powertrain types—positions it well to navigate evolving market trends.
The analyst also highlighted that BorgWarner has a number of upcoming product launches with domestic Chinese auto OEMs, further strengthening its foothold in this key market.
With higher content per vehicle opportunities in both hybrid and battery electric vehicles, BorgWarner is expected to benefit from the rising share of hybrid volumes in the near to medium term.
While its eProduct division is still operating at a loss, the analyst stated that ongoing restructuring efforts, coupled with long-term growth, will help the company move toward profitability.
Price Action: BWA shares closed lower by 4.54% to $25.67 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns" target="_blank" rel="noreferrer noopener">China's Growth Outlook Dims As Trump's 125% Tariffs Put Millions Of Jobs At Risk, Goldman Warns</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Analyst Color

Price Target

BorgWarner Has Hidden Value In A Hybrid-Heavy Future: Analyst

YCBD

cbdMD Shareholders Approve Automatic Conversion Of Series A Preferred Stock And Other Results From Annual Meeting

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $132.56, a high estimate of $153.00, and a low estimate of $110.00. Observing a downward trend, the current average is 4.78% lower than the prior average price target of $139.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322499_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Crocs among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$138.00 &#x7C; 
&#x7C;Laura Champine &#x7C;Loop Capital &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Raises &#x7C;Neutral &#x7C; $132.00&#x7C;$122.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $122.00&#x7C;$125.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $153.00&#x7C;$144.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $150.00&#x7C;$180.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$155.00 &#x7C; 
&#x7C;Ashley Owens &#x7C;Keybanc &#x7C;Lowers &#x7C;Overweight &#x7C; $120.00&#x7C;$150.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Crocs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Crocs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Crocs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Crocs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CROX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Crocs analyst ratings.</a>
<h2>Delving into Crocs's Background</h2>
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
<h3>Breaking Down Crocs's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Crocs displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.09%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Crocs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 37.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Crocs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 20.72%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Crocs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.75% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.93, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CROX

Assessing Crocs: Insights From 9 Financial Analysts

Across the recent three months, 4 analysts have shared their insights on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $258.75, a high estimate of $265.00, and a low estimate of $240.00. Marking an increase of 0.49%, the current average surpasses the previous average price target of $257.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322492_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Turkaly &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Reni Benjamin &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $265.00&#x7C;$265.00 &#x7C; 
&#x7C;Jacob Johnson &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $240.00&#x7C;$240.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $265.00&#x7C;$260.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Steris's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Steris's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Steris showcased positive performance, achieving a revenue growth rate of 5.61% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin is impressive, surpassing industry averages. With a net margin of 12.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Steris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.71%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Steris Stock

Across the recent three months, 7 analysts have shared their insights on Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Skechers USA, presenting an average target of $77.0, a high estimate of $90.00, and a low estimate of $62.00. Highlighting a 4.26% decrease, the current average has fallen from the previous average price target of $80.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322485_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Skechers USA is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $62.00&#x7C;$80.00 &#x7C; 
&#x7C;Christopher Nardone &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$76.00 &#x7C; 
&#x7C;Adrienne Yih &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $77.00&#x7C;$80.00 &#x7C; 
&#x7C;Rick Patel &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $75.00&#x7C;$80.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $80.00&#x7C;$83.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $90.00&#x7C;$92.00 &#x7C; 
&#x7C;JESALYN Wong &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $85.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Skechers USA. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Skechers USA compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Skechers USA's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Skechers USA's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SKX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Skechers USA analyst ratings.</a>
<h2>All You Need to Know About Skechers USA</h2>
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
<h3>Understanding the Numbers: Skechers USA's Finances</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Skechers USA's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 12.82%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: Skechers USA's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 4.49%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Skechers USA's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.3%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Skechers USA's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.45, Skechers USA adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Skechers USA Through 7 Analysts

21 analysts have expressed a variety of opinions on GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for GE Vernova, presenting an average target of $430.57, a high estimate of $500.00, and a low estimate of $370.00. Marking an increase of 3.69%, the current average surpasses the previous average price target of $415.24. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322476_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of GE Vernova among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $425.00&#x7C;$436.00 &#x7C; 
&#x7C;Charles Minervino &#x7C;Susquehanna &#x7C;Announces &#x7C;Positive &#x7C; $370.00&#x7C;- &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $413.00&#x7C;$391.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $445.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Announces &#x7C;Buy &#x7C; $380.00&#x7C;- &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $420.00&#x7C;$471.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $427.00&#x7C;$487.00 &#x7C; 
&#x7C;Ben Kallo &#x7C;Baird &#x7C;Announces &#x7C;Outperform &#x7C; $448.00&#x7C;- &#x7C; 
&#x7C;Martin Malloy &#x7C;Johnson Rice &#x7C;Announces &#x7C;Buy &#x7C; $425.00&#x7C;- &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $453.00&#x7C;$453.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Neutral &#x7C; $380.00&#x7C;$380.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $500.00&#x7C;$446.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $470.00&#x7C;$420.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $471.00&#x7C;$420.00 &#x7C; 
&#x7C;Andrew Kaplowitz &#x7C;Citigroup &#x7C;Raises &#x7C;Neutral &#x7C; $437.00&#x7C;$361.00 &#x7C; 
&#x7C;Julian Mitchell &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $487.00&#x7C;$420.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $436.00&#x7C;$374.00 &#x7C; 
&#x7C;Joe Ritchie &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $446.00&#x7C;$400.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $420.00&#x7C;$400.00 &#x7C; 
&#x7C;Andrew Obin &#x7C;B of A Securities &#x7C;Raises &#x7C;Buy &#x7C; $415.00&#x7C;$380.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $374.00&#x7C;$367.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to GE Vernova. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GE Vernova compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for GE Vernova's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of GE Vernova's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on GE Vernova analyst ratings.</a>
<h2>Delving into GE Vernova's Background</h2>
GE Vernova is a global leader in the electric power industry, with products and services that generate, transfer, convert, and store electricity. The company has three business segments: power, wind, and electrification. Power includes gas, nuclear, hydroelectric, and steam technologies, providing dispatchable power. The wind segment includes wind generation technologies, inclusive of onshore and offshore wind turbines and blades. Electrification includes grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, and storage of electricity from the point of generation to point of consumption.
<h3>A Deep Dive into GE Vernova's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Over the 3M period, GE Vernova showcased positive performance, achieving a revenue growth rate of 5.11% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: GE Vernova's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): GE Vernova's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.08%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): GE Vernova's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.95% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: GE Vernova's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying GE Vernova: Insights From 21 Analyst Reviews

5 analysts have shared their evaluations of Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $142.6, a high estimate of $150.00, and a low estimate of $129.00. Observing a downward trend, the current average is 0.83% lower than the prior average price target of $143.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1744322469_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Addus HomeCare is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Constantine Davides &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $150.00&#x7C;$150.00 &#x7C; 
&#x7C;Scott Fidel &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C; 
&#x7C;Tao Qiu &#x7C;Macquarie &#x7C;Maintains &#x7C;Outperform &#x7C; $129.00&#x7C;$129.00 &#x7C; 
&#x7C;Raj Kumar &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Overweight &#x7C; $142.00&#x7C;$153.00 &#x7C; 
&#x7C;Ari Wald &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $150.00&#x7C;$145.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Addus HomeCare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Addus HomeCare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Addus HomeCare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Addus HomeCare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Addus HomeCare analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Addus HomeCare</h2>
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
<h3>A Deep Dive into Addus HomeCare's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Addus HomeCare's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.52%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Addus HomeCare's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 6.57%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Addus HomeCare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Addus HomeCare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.52%, the company showcases efficient use of assets and strong financial health.
Debt Management: Addus HomeCare's debt-to-equity ratio is below the industry average at 0.28, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

What Analysts Are Saying About Addus HomeCare Stock

In the current market session, Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) stock price is at $164.31, after a 3.75% decrease. However, over the past month, the company's stock went up by 2.04%, and in the past year, by 48.85%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_0.png" alt="Past Year Chart" />

<h3>A Look at Interactive Brokers Group P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 18.84 in the Capital Markets industry, Interactive Brokers Group Inc. has a higher P/E ratio of 24.63. Shareholders might be inclined to think that Interactive Brokers Group Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744322460_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

IBKR

P/E Ratio Insights for Interactive Brokers Group

Press Releases

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Small Cap

Opinion

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Health Care

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contracts

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Earnings

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Comments

Xilio Therapeutics

Interés en corto

Xilio Therapeutics (NASDAQ:XLO) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL